Zhejiang Hisoar Pharmaceutical Hits Day Low at CNY 7.95 Amid Price Pressure

Zhejiang Hisoar Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 8.27% as it reached an intraday low of CNY 7.95. This performance stands in stark contrast to the China Shanghai Composite, which fell by only 1.26% on the same day. Over the past week, Zhejiang Hisoar has shown a positive trend, gaining 8.29%, and it has performed well over the past month with a 29.19% increase. However, the stock's one-year performance reveals a more complex picture, with a modest return of 0.63%, significantly lagging behind the market's 15.18% return. Financial metrics indicate challenges for the company, including a low Return on Capital Employed (ROCE) of 2.16%, reflecting limited profitability relative to its capital. Additionally, the company has faced declining net sales growth at an annual rate of -6.39% over the last five years, alongside a concerning operating profit decline of 180.98%. With a market capitalization of CNY 11,906 million, Zhejiang Hisoar operates within the pharmaceuticals and biotechnology sector, but its recent performance raises questions about its financial health and market position.